Narendranath Epperla
Huntsman Cancer Institute · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Narendranath Epperla as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07573436 · Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)University of Utah · recruiting · Post-transplant Lymphoproliferative Disorder · principal investigator
- Ph1NCT07049432 · N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasUniversity of Utah · withdrawn · B-cell Non Hodgkin Lymphoma · principal investigator
- Ph1NCT06824701 · Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah · active not recruiting · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT06788964 · Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)University of Utah · recruiting · Relapsed or Refractory Large B-cell Lymphoma · principal investigator
- Ph1NCT06607549 · Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)University of Utah · recruiting · Central Nervous System Lymphoma · principal investigator
- Ph2NCT06300528 · Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasUniversity of Utah · active not recruiting · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma · principal investigator
- Ph1NCT04836832 · Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaNarendranath Epperla · withdrawn · Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · fiscal years 2025 to 2026 · $1,697,412 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:05 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy.Br J Haematol · 202083 citationsRCR 5.1
- Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.Clin Cancer Res · 202151 citationsRCR 2.5
- Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.Blood Adv · 201931 citationsRCR 1.0
- Outcomes after stereotactic radiosurgery for CNS lymphoma.J Neurooncol · 202015 citationsRCR 0.9
- Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.Am J Hematol · 20175 citationsRCR 0.2
- Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.Clin Cancer Res · 20205 citationsRCR 0.2